BACKGROUNG For a long time, laryngopharyngeal reflux disease (LPRD) has been treated by proton pump inhibitors (PPIs) with an uncertain success rate.
Author contributions: Lechien JR, Mouawad F, Saussez S, Eun Y substantial contributed to the conception or design of the work; made the acquisition, analysis, or interpretation of data for the work; drafted the work; made final approval of the version to be published; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Barillari M and Calvo-Henriquez C substantial contributed to the conception or design of the work; made the acquisition (systematic review performing); made the interpretation of data; agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Khoddami SM, Raghunandhan SK, Enver N, Nacci A made the interpretation of data, discussion improvement, agreement to be accountable for all aspects of the work in ensuring that questions related to the INTRODUCTION Laryngopharyngeal reflux disease (LPRD) is an inflammatory condition of the upper aerodigestive tract tissues related to direct and indirect effect of gastric or duodenal content reflux, which induces morphological changes in the upper aerodigestive tract [1] . LPR-related symptoms concern approximately 4 to 10% of outpatients visiting Otolaryngology-Head and Neck Surgery Departments [2] and up to 50% of patients in Division of Laryngology [3] . To date, several controversies persist about the diagnostic and the therapeutic management of LPRD. Although proton pump inhibitors (PPIs) are considered as the main treatment of LPRD since many decades [4] , the superiority of PPIs over placebo is still controversial [5] . Thus, more than 40% of patients have less or no symptom relief with an empirical therapeutic trial based on PPIs [5, 6] . The aim of this systematic review is to shed light the current therapeutic strategies used for the management of LPRD in order to analysis the rationale in the treatment of LPRD.
MATERIALS AND METHODS
The criteria for considering studies for the review were based on the population, intervention, comparison, and outcome framework [7] .
Types of studies
Clinical prospective or retrospective studies published in peer-reviewed journals were included. Studies had to explore the impact of medical treatment(s) on the clinical presentation of suspected or confirmed LPRD. Only studies published in English literature were included.
Participants, inclusion/exclusion criteria
Papers were included if they attempted rigorous diagnosis of LPRD through symptoms, exam findings, or objective testing. Patients with positive pH-monitoring or multichannel intraluminal impedance-pH monitoring (MII-pH) were considered as "LPRD patients"; those with a clinical diagnosis based on symptoms ± findings were considered as "suspected LPRD patients". Studies focusing on patients who did not respond to treatment were not included.
Outcomes
The primary outcome was review of types and effectiveness of treatment administered to LPRD patients. The secondary outcome was based on the above to define a rational approach to the management of LPRD.
Intervention and comparison
Authors had to treat their patients with conventional medical treatment including PPIs, prokinetics, histamine H 2 -receptor antagonists (H 2 R), alginate, magaldrate, baclofen and other drugs that have been reported at least once as treatment of LPRD or gastroeosophageal reflux disease (GERD). Diet and behavioral changes have also been considered as treatment. Studies that reported patients treated with surgery were carefully excluded. The studies had to clearly describe the therapeutic scheme, i.e., drug(s), doses and potential association of drug(s) with other therapeutic approaches (speech and swallowing therapies, etc.).
Search strategy
Lechien JR, Barillari MR, and Calvo-Henriquez C conducted a PubMed search to identify papers published between January 1990 and February 2019. Studies were screened if they had database abstracts, available full texts or titles referring to the condition. The following keywords were used: "Laryngopharyngeal reflux"; "reflux laryngitis"; "gastroesophageal reflux"; "treatment"; and "therapeutic". These investigators provided a critical analysis of the publication's content and summarized the data of the selected papers in the publication in order to determine final article selection.
RESULTS
The search identified 1355 relevant papers, of which 76 studies met the inclusion criteria, accounting for 6457 patients. A total of 64 studies consisted of empirical therapeutic trials (Table 1) , and 12 were studies where authors formally identified LPRD with pH-monitoring (n = 10) or MII-pH (n = 2) ( Table 2) [40, 56, 60, [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] .
The main therapeutic scheme consisted of once or twice daily PPIs (n = 63) for a duration ranged from 4 to 24 wk. The most used PPIs were omeprazole, esomeprazole, rabeprazole, lansoprazole and pantoprazole ( Table 3 ). The efficacy of these treatments was reported in the majority of studies using different outcomes, yielding the comparison between studies difficult (Tables 1 and 2) . Overall, authors reported a success rate with PPI therapy ranging from 18% to 87%. Other composite treatments have been prescribed including PPIs, alginate, prokinetics, and H 2 R antagonists (Table 4 ).
DISCUSSION
LPRD has been defined as a different entity other than GERD in the end of the nineties [84] . Since then, the number of clinical studies dedicated to the treatment of LPRD have progressively increased [1] . This review has shown that the most preferred treatment for LPRD is still the administration of once or twice daily PPIs. This therapeutic approach is however associated with an uncertain success rate and, Hanson et al [8] , 1995 Pros Uncontr IIIb Suspected LPR (n = 141) Symptom and sign resolution: 51% 4 wk omeprazole (20 mg, 1/d) and diet Jaspersen et al [9] [11] , 1997 Pros Uncontr IIIb Suspected LPR (n = 21) Pre to post-score improvement: + 8 wk omeprazole (40 mg, 1/d) and diet Metz et al [12] , 1997 Pros Uncontr IIIb Suspected LPR (n = 10) Symptom and sign resolution: 60% 4 wk omeprazole (20 mg/d) Habermann et al [13] , 1999
Pros Uncontr IIIb Suspected LPR (n = 29) Pre to post-score improvement: + 6 wk pantoprazole (40 mg/d) Havas et al [14] , 1999 Placebo RCT Ib Gr1: suspected LPR (n = 7)
Pre to post-score improvement: + Gr1-2: 12 wk placebo/lanzoprazole (30 mg 2/d) and Diet Gr2: suspected LPR (n = 8)
El-Serag et al [15] , 2001
Placebo RCT Ib Gr1: suspected LPR (n = 10)
54% of symptom resolution Gr1-2: 12 wk placebo/lansoprazole (30 mg 2/d) Gr2: suspected LPR (n = 10)
Langevin et al [16] , 2001 Placebo RCT Ib Gr1: suspected LPR (n = 14)
Pre to post-score improvement Gr1-2: 12 wk placebo/omeprazole (40 mg/d) Gr2: suspected LPR (n = 16)
Hamdan et al [17] , 2001 Pros Uncontr IIIb Suspected LPR (n = 22) Pre to post-score improvement: + 4 wk pantoprazole (40 mg, 2/d), cisapride (20 mg, 2/d) and diet
Rodríguez-Téllez et al [18] , 2002
Pros Uncontr IIIb Suspected LPR (n = 21) Pre to post-score improvement: + 12 wk omeprazole (20 mg, 2/d) Habermann et al [19] , Pre to post-RSI improvement Gr1-2: 24 wk placebo/gaviscon (4/d) and diet Gr2: suspected LPR (n = 25)
Vashani et al [35] , 2010
Placebo Pre to post-RFS improvement: -Lam et al [37] , 2010
Placebo RCT Ib Gr1: suspected LPR (n = 42)
Pre to post-RSI and RFS improvement: + Becker et al [47] , 2012 Pros Uncontr IIIb Suspected LPR (n = 30) Reduction of RSI: 20% 12 wk pantoprazole (40 mg, 2/d) Hunchaisri et al [48] , 2012 Chappity et al [55] , 2014 RCT IIb Gr1: suspected LPR (n = 117)
Pre to post-score improvement: + Batıoğlu-Karaaltın et al [61] , 2016 [65] , 2017
Retrospective IV Gr1: suspected LPR (n = 85)
Reduction of ≥ 6-points of RSI Gr1-2: 54-63% [72] , 2019 Pros Contro IIb Gr1: suspected LPR (n = 20)
Pre to post-RSI, RFS improvement: + depending of the therapeutic outcomes used, a significant number of patients are found to be resistant to treatment. According to a recent systematic review, the nonresponse rate would be close to 40% of patients [85] . The critical analysis of the different therapeutic schemes and their related success rate has to consider the respective pharmacological properties of the drugs used.
PPIs
PPI decreases the H+ gastric secretion by covalent binding with H+/K+ ATPase. The inhibition of proton pump increases the pH of the gaseous refluxate droplets and limits the extracellular activity of pepsin on upper aerodigestive tract tissues [86] . From a pathophysiological standpoint, PPIs have no impact on the intracellular activity of pepsin [87] , and a low impact on the activity of trypsin and non-conjugated bile salts, which could injure the laryngopharyngeal mucosa in a nonacid environment [88, 89] . Moreover, the PPI intake does not change the total number of daily reflux episodes [90] . This review shows that the doses and administration frequency of PPIs varies from one to another study. PPIs have a short half-life (90 min) and an oral unique dose of 20 mg inhibits 70% of the pump enzymes [91] . In practice, the half-life of the inhibition of gastric acid secretion lasts an estimated 24 h. Approximately 20% of proton pumps are newly synthesized over a 24-h period with greater pump synthesis at night than during the day. With regard to the 90 min blood half-life of PPI, the addition of bedtime administration will not add to inhibition of nocturnal acid breakthrough, because the drug will have disappeared by the time nighttime acid secretion is evident. Assuming that about 70% of pumps are activated by breakfast and that the PPI is given 30 to 60 min beforehand, it can be calculated that steady state inhibition on once-a-day dosing is about 66% of maximal acid output. In other words, and regarding the pharmacological properties of the drug, increasing the dose has virtually no effect once optimal dosage has been reached. However, increasing the dose frequency does have some effect; a morning dose and an evening dose before meals results in about 80% inhibition of maximal acid output [91, 92] . Thus, twice daily PPI could be better because a more complete control of both daytime and nocturnal esophageal acid exposure [93] . In LPRD literature, only the study by Park et al [28] compared once vs twice daily PPIs in LPRD. These authors suggested a superiority of twice daily vs once daily PPI(s), which seems to be in accordance with the pharmacological properties of PPIs [28, 93] . Pharmacologically, the use of twice daily 20 mg PPIs could be the most effective approach in order to inhibit the acid secretion but, as mentioned above, this approach has low effect on nonacid or weakly acid LPRD variants. [76] , 2003 Placebo RCT Ib Gr1: LPR (n = 7); Gr2: LPR (n = 7)
Symptom/sign improvement: 80%-100% 
Histamine H 2 R
PPIs have been associated with H 2 R in four studies [28, 66, 70, 72] . In comparison with twice daily PPIs, the use of H 2 R does not make sense regarding their short duration of action (6 to 12 h) [94, 95] . The studies comparing the efficacy of PPIs vs H 2 R + PPIs did not report a clinical evidence of the use of H 2 R in LPRD [28, 72] . Moreover, the association of once daily PPI with ranitidine at bedtime being more expensive approach than 6-mo twice daily PPIs [66] .
Prokinetics
The addition of prokinetics to PPIs is still controversial in GERD [96] , despite their role in the increase of the esophageal sphincter pressure [94, 97, 98] . Six studies showed interest in the role of prokinetics for the management of LPRD [17, 38, 48, 51, 57, 79] and these authors reported mixed evidence about the superiority of PPIs and prokinetics over PPIs alone [99] . Precisely, two RCTs suggested that the addition of prokinetics to PPI(s) would be associated with better symptom improvement [38, 51] , while the study by Hunchaisri et al [48] did not find similar findings. The controversy about the efficacy of prokinetics in LPRD illustrates the lack of evidence in the occurrence of esophageal dysmotility disorder in this condition [100, 101] .
Alginate and magaldrate
The development of MII-pH led to the identification of new subtypes of LPRD, being acid, weakly acid, mixed and nonacid LPRD. In that way, three recent studies found that the majority of patients have in fact nonacid or mixed LPRD [102] [103] [104] . The pathophysiological mechanisms of nonacid and mixed LPRD are still unknown but they could involve the activity of trypsin, conjugated and non-conjugated bile salts in the mucosa of the upper aerodigestive tract [1, 105] . Precisely, non-conjugated bile salts and trypsin are effective in pH above 6.0 while conjugated bile salts are more effective in acid environment. Consequently, the use of alginate or magaldrate could make sense in the primary management of LPRD. Alginates form a raft floating over gastric contents that can be maintained within the stomach for up to 4 h. Gaviscon is endowed with bio-adhesive potential, a property due primarily to its polymer chain length and ionizable groups that provides a protective biofilm on the mucosa of esophagus and, potentially, upper aerodigestive tract [106] . Interestingly, these drugs are able to reduce the number of acid reflux events [94, 107] .
In practice, McGlashan et al [34] have demonstrated the superiority of alginate over placebo in the treatment of LPRD patients. More recently, Wilkie et al [69] found that a treatment based on the single use of alginate is quite competitive with a treatment combining PPIs and alginate. Our recent results also support that the addition of alginate or magaldrate to PPIs seems to significantly improve symptoms in patients with mixed and nonacid LPRD [102] .
Diet and behavioral changes
Diet and behavioral changes remain the first therapeutic step of the LPRD treatment. Additionally, this approach is the best cost-effective empirical treatment for patients with mild LPRD. In practice, patients who respect diet and behavioral changes have better symptom improvement than those who did not respect diet [108] . Furthermore, recent studies suggested that a well-conducted diet could be as efficiently as PPI treatment [65, 70] . Alkaline, protein, low-fat and low-acid diet is effective because these types of foods are well digested, also decreasing the number of transient relaxations of esophageal sphincters and thereby the related number of LPRD episodes. improvement of daily clinical practices related to LPRD. MII-pH studies showed that there are a large number of patients with nonacid or mixed LPRD, which are both less controlled by conventional PPI therapy. It is highly likely that a significant part of the patients who were called "resistant LPRD patients" within the three last decades, had nonacid or mixed LPRD. With regard to the properties of anti-reflux drugs, alginate is a future candidate as single drug or additional drug to PPIs in the future studies. The concomitant use of twice daily PPIs and twice or thrice daily alginate or magaldrate could provide a consistent protection against the mucosal irritation of pepsin, trypsin and bile salts. Naturally, the administration of diet and behavioral changes is still required in all patients in order to improve the treatment efficacy. According to a recent management algorithm of LPRD (Figure 1) [1] , MII-pH testing could be used as diagnostic and therapeutic control tool, providing better identification of the LPRD subtypes and better treatment. Because the compliance of LPRD patients to medical treatment and diet can be poor, the administration of a personalized treatment based on the patient MII-pH results and the lifestyle habits could improve the patient compliance to LPRD treatment. In this algorithm, proximal reflux event was defined as an episode that reached two impedance sensors in the hypopharynx or proximal esophagus. Acidic event consisted of a gaseous or liquid reflux with a pH ≤ 4.0 while nonacidic event was a gaseous or liquid reflux with a pH > 4.0. The LPR diagnosis was based on the occurrence of ≥ 1 proximal episode. Acid reflux episode consisted of an episode with pH > 4.0. Nonacid reflux episode consisted of an episode with pH ≤ 4.0. Because there are no guidelines in the definition of acid, nonacid and mixed laryngopharyngeal reflux disease (LPRD) disease, LPRD was defined as acid when the ratio of number of acid reflux episodes/number of nonacid reflux episodes was > 2. LPRD was defined as nonacid when the ratio of number of acid reflux episodes/number of nonacid reflux episodes < 0.5. Mixed reflux consisted of a ratio ranged from 0.51 to 2.0. 1 For nonacid LPR, PPIs are not necessary regarding their low efficacy.
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Research background
For a long time, laryngopharyngeal reflux disease (LPRD) has been treated by proton pump inhibitors (PPIs) with an uncertain success rate.
Research motivation
The low success rate of PPIs as well as the cost of unsuccessful empirical therapeutic trials are important in otolaryngology. Many treatments of LPRD exist and we want to provide an analysis of the current therapeutic approach of this prevalent disease.
To shed light the current therapeutic strategies used for LPRD in order to analysis the rationale in the LPRD treatment.
Research methods
Three authors conducted a PubMed systematic review respecting PRISMA statements.
